Epivir HBV and Insulin glargine and lixisenatide Subcutaneous
Determining the interaction of Epivir HBV and Insulin glargine and lixisenatide Subcutaneous and the possibility of their joint administration.
No interaction was detected between the selected drugs or effects of joint drug administration are currently understudied, and it takes time and accumulated statistics to determine their interaction. A doctor should be consulted to address the issue of joint drug administration.
Generic Name: lamivudine
Brand name: Epivir, Epivir HBV
Synonyms: Epivir-HBV
Generic Name: insulin glargine / lixisenatide
Brand name: Soliqua 100/33
Synonyms: Insulin glargine and lixisenatide (Subcutaneous)
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Epivir HBV-Insulin glargine, recombinant Subcutaneous
- Epivir HBV-Insulin glulisine
- Epivir HBV-Insulin Glulisine (Cartridges and Pens)
- Epivir HBV-Insulin Glulisine (Vials)
- Epivir HBV-Insulin glulisine Subcutaneous
- Epivir HBV-Insulin human inhaled Inhalation
- Insulin glargine and lixisenatide Subcutaneous-Epivir-HBV (Lamivudine Oral Solution)
- Insulin glargine and lixisenatide Subcutaneous-Epivir-HBV (Lamivudine Tablets)
- Insulin glargine and lixisenatide Subcutaneous-Eplerenone
- Insulin glargine and lixisenatide Subcutaneous-Epoetin alfa
- Insulin glargine and lixisenatide Subcutaneous-Epoetin alfa Injection
- Insulin glargine and lixisenatide Subcutaneous-Epoetin Alfa Vials